Alfa Thermodiagnostics is the leader in next-generation, non-invasive medical thermometry, providing solutions to physicians to discover and remediate disease. The company has engineered an FDA-cleared, whole-body early-detection system as an adjunct diagnostic tool, called AlfaSight™. AlfaSight™ is grounded in the established science of regulation thermography which was commercialized in Germany more than 25 years ago.
The AlfaSight™ regulation thermometry™ system provides a visual representation of the responsiveness of the autonomic nervous system, which can uncover the causal factors of many diseases. It is a proven, accurate technology supported by more than 100,000 patient assessments, and has been clinically correlated with hundreds of MRI & CT scans. AlfaSight™ is significantly different from infrared camera technology, which captures heat map images.
Founder Dr. Daniel Beilin led the United States FDA clearance of the first-generation regulation thermography technology in 1996 and also ushered Alfa's next-generation regulation thermometry™ system through FDA clearance. He is recognized worldwide as the foremost authority on whole-body thermometry and is supported by leaders in the fields of radiology, neurobiology and regulation medicine.
AlfaSight™ is a non-invasive patient assessment tool that identifies a wide range of physiological dysfunction by analyzing skin temperature changes over time. It can dramatically improve the accuracy of routine testing for a wide range of impaired health conditions when used as an adjunct technology to mammography and other anatomical imaging devices.
AlfaSight™ has obtained FDA 510(k) clearance, CE mark and Health Canada licensing, and is available for purchase in the United States, Canada, European Economic Area (EEA) countries and Asian Markets.
For more information, contact us.